The unique applications of nucleic acid aptamers and their
expanding properties across various sectors is fueling the nucleic
acid aptamers market growth. Aptamers are being explored in drug
delivery systems, personalized medicines, biomarker discovery, and
biosensors.
WILMINGTON, Del., July 29, 2024 /PRNewswire/ -- The nucleic acid
aptamers market is poised for remarkable growth in the coming
decade. TMR forecasts the industry to register a staggering
17.2% CAGR from 2024 to 2034. By the conclusion of this
forecast period, a valuation of US$ 1.2
billion is expected to be realized.
Since their discovery in the 1990s, several attempts have been
made to utilize aptamers as clinical agents for diseases such as
AIDS and macular degeneration. It is important to note that the
first aptamer-based therapeutic to receive U.S. FDA approval was
Macugen (Pegaptanib), that acts as a selective antagonist of
vascular endothelial growth factor (VEGF) and is indicated for the
treatment of patients suffering from neovascular age-related
macular degeneration.
With the surging prevalence of chronic disorders such as cancer,
diabetes and cardiovascular conditions, the demand for highly
efficient diagnostic and therapeutic strategies is rising. In this
context, in 2022, global cancer statistics suggest that nearly 20
million new cases of cancer were reported while the cancer-related
mortality toll stood at 9.7 million.
Request for sample PDF copy of report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1330
Aptamers are more effective than the conventional approaches
used for cancer therapy. The development of aptamers and potential
conjugates has made it simple and extremely efficient to distribute
medications in a targeted and selective manner.
Recent advancements in SELEX (Systematic Evolution of Ligands
through Exponential Enrichment) methods have enabled the screening
and filtering of aptamer probes with extremely high specificity to
bind to targets, from a library of 1013 to
1016 single-stranded RNA or DNA molecules.
Key Takeaways from the Market Study
- The nucleic acid aptamers market is forecast to total
US$ 245.4 million in 2024.
- From 2024 to 2034, the market for nucleic acid aptamers is
slated to expand nearly 5x.
- By indication, nucleic acid aptamers are expected to be used
extensively for ophthalmology.
- DNA aptamers are anticipated to remain in high demand
throughout the forecast period.
- Disease recognition to emerge as an important application area
for nucleic acid aptamers.
- Nucleic acid aptamers are expected to be used widely by
biopharmaceutical companies.
Market Drivers and Trends
- Increase in prevalence of chronic and infectious diseases is
anticipated to drive the nucleic acid aptamer market growth during
the forecast period. Chronic diseases such as cancer, diabetes, and
cardiovascular diseases, as well as infectious diseases including
HIV, hepatitis, and emerging viral infections, require precise and
early diagnosis for effective treatment.
- Nucleic acid aptamers, with their high specificity and affinity
for target molecules, are being developed for use in advanced
diagnostic assays that can detect diseases at earlier stages with
greater accuracy.
Unlock Growth Potential in Your Industry! Download PDF
Brochure:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1330
Region-wise Analysis
- The United States is expected
to be a major hub for nucleic acid aptamer sales in the coming
decade. This is attributed to the fact that the country is an
emerging hub for innovations in the pharmaceutical and biological
spaces.
- Significant investments in research and development in the
region have propelled advancements in aptamer technology, including
improved selection methods, enhanced binding affinities, and novel
applications in drug delivery and diagnostics.
- Regulatory bodies such as the FDA in the U.S. play a vital role
in shaping the nucleic acid aptamer market, providing guidance and
approval pathways for aptamer-based products, ensuring safety,
efficacy, and compliance with regulatory standards. This boosts
nucleic acid aptamers market value and commercialization.
- Various product approvals associated with ophthalmology are
expected to drive market progress in North America. For instance, in August 2023, FDA approved the second RNA aptamer,
Izervay for treatment of geographic atrophy (GA) secondary to
age-related macular degeneration.
Nucleic Acid Aptamers Market Report Scope:
Report
Coverage
|
Details
|
Forecast
Period
|
2024-2034
|
Base
Year
|
2020-2022
|
Size in 2023
|
US$ 219.9 Mn
|
Forecast (Value) in
2034
|
US$ 1.2 Bn
|
Growth Rate
(CAGR)
|
17.2 %
|
No. of
Pages
|
174
Pages
|
Segments
covered
|
By Type, By
Application, By Indication, By Region, By End-user
|
Competitive Landscape
The global market for nucleic acid aptamers is characterized by
the presence of a large number of players. This renders the
landscape highly fragmented and competitive. Market players are
leveraging the potential of collaborations to introduce
cutting-edge product lines.
Besides collaborations, players are vying for the top space with
regards to obtaining licenses and certifications. Seeking approvals
from regulatory authorities provides them with an opportunity to
expand their product base and reach a wider target audience.
Key Market Players Profiled
- Aptagen Labs
- Aptamer Group
- Base Pair Biotechnologies
- NeoVentures Biotechnology Inc.
- Aptamer Sciences Inc.
- SomaLogic Operating Co. Inc.
- AptaTargets SL.
- Aptus Biotech S.L.
- Other Prominent Players
Prominent Market Developments
- In February 2023,
Aptamer Group, a company which focuses on developing
innovative novel binders across its Optimer-based platform,
revealed a new link-up with BaseCure Therapeutics. The partnership
will primarily concentrate on emerging Optimer-targeted gene
therapies.
- In October 2022,
QIAGEN N.V., announced certification of its leading in-vitro
diagnostic (IVD) kit and its fully automated NeuMoDx platforms
under the European Union's new In-Vitro Diagnostic Medical Devices
Regulation (IVDR), replacing the previous IVDD rules since
May.
- The ipsogen JAK2 RGQ PCR kit used for myeloproliferative
neoplasms (MPN), a certain type of blood cancer, is now QIAGEN's
first IVD kit with IVDR CE-marking under Class C.
Key Segments Covered
Type
- DNA Aptamer
- RNA Aptamer
- XNA Aptamer
Application
- Drug Delivery
- Anti-viral Therapy
- Pathogen Recognition
- Disease Recognition
- Stem Cell Markers
- Others
Indication
- Viral Infection
- Cancer
- Ophthalmology
- Others
End User
- Biopharmaceutical Companies
- Diagnostic Centers
- CROs
- Others
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Buy this Premium Research Report:
https://www.transparencymarketresearch.com/checkout.php?rep_id=1330<ype=S
More Trending Reports by Transparency Market Research
–
- Healthcare Automation Market – The Global
Healthcare Automation Market Size Worth USD
88.9 Bn in 2028 Growing at a CAGR of 8.4%, TMR Study
- Durable Medical Equipment (DME) Market – The
Global Durable Medical Equipment Market to Reach US$ 261 Bn by 2027, TMR Study
- Lucid Dreaming Devices Market – The Global Lucid
Dreaming Devices Market is expected reach US$ 196.8 Million by the end of 2034
- Low Endotoxin Gelatin Market - The Global Low
Endotoxin Gelatin Market is expected to grow at a CAGR of 6.4% from
2024 to 2034.
About Transparency Market Research
Transparency Market Research, a global market research
company registered at Wilmington, Delaware, United States, provides custom research and
consulting services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insights
for thousands of decision makers. Our experienced team of Analysts,
Researchers, and Consultants use proprietary data sources and
various tools & techniques to gather and analyses
information.
Our data repository is continuously updated and revised by a
team of research experts, so that it always reflects the latest
trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary
and secondary research techniques in developing distinctive data
sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE
HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware
19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free:
866-552-3453Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter|
Blog | YouTube
Logo:
https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/nucleic-acid-aptamers-market-to-reach-usd-1-2-billion-by-2034-unique-applications-in-drug-delivery--personalized-medicine-driving-growth--tmr-302208443.html